Reuters: Mergers News: UPDATE 1-Illumina sued by Columbia Univ. over DNA patents

Reuters: Mergers News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-Illumina sued by Columbia Univ. over DNA patents Mar 26th 2012, 14:39 Mon Mar 26, 2012 10:39am EDT * Columbia: Five patents tied to DNA sequencing infringed * Royalties, triple damages sought * Illumina fending off Roche $5.7 billion hostile takeover March 26 (Reuters) - Illumina Inc, facing a hostile takeover bid by Swiss drugmaker Roche Holding AG, was sued by Columbia University on Monday for alleged infringement of five patents related to DNA sequencing. According to the complaint filed in the U.S. District Court in Wilmington, Delaware, Illumina commercialized its so-called next-generation sequencing (NGS) products despite knowing about the patents, which were obtained between 2009 and 2012 and assigned to Columbia. The university said its patents cover NGS technologies that allow rapid and precise DNA sequencing. It said the technologies are particularly important in personalized medicine, in which individuals' genomic DNA sequence information is used as a basis to provide health care. Illumina makes machines that decode a person's entire genome. Representatives of the company did not immediately respond to requests for comment. A lawyer for Columbia also did not immediately respond to a request for comment. Columbia's lawsuit seeks royalties, triple damages and other remedies. The complaint was filed hours after Roche extended its $5.7 billion cash takeover bid for Illumina, which values the San Diego-based company at $44.50 per share. Illumina considers the offer "grossly inadequate." Acquiring the company would give Roche a leading position in gene sequencing, which could help better identify which patients might benefit from using particular drugs. Analysts expect Roche to raise its offer. Illumina's shares have traded above $44.50 since the bid became public on Jan. 25. In Monday trading, Illumina shares were down 53 cents at $49.93 on the Nasdaq. Illumina in 2011 posted profit of $86.6 million on revenue of $1.06 billion. In its annual report, the company projected that expansion in the sequencing market and its product portfolio would drive demand for its technology over the next several years. The case is Trustees of Columbia University in the City of New York v. Illumina Inc, U.S. District Court, District of Delaware, No. 12-00376. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions